Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation and Expansion Trial With the SIRPα-directed Monoclonal Antibody BYON4228 Alone and in Combination to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Advanced or Metastatic Solid Tumors

NCT06932952 is registered in ClinicalTrials.gov with Byondis B.V. as lead sponsor.

NCT NCT06932952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06932952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation and Expansion Trial With the SIRPα-directed Monoclonal Antibody BYON4228 Alone and in Combination to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Advanced or Metastatic Solid Tumors
Lead sponsor
Byondis B.V.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 7, 2025
Completion date
December 31, 2026
Enrollment
7 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor